Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965271 | 0.96 | RAB9A (0.39) | RAB9ANPC1ALDH1A1NOTUMALOX15 | |
| SCHEMBL2825141 | 0.78 | NPC1 (0.39) | RAB9ANPC1ALDH1A1NOTUMTSHR | |
| SCHEMBL6474512 | 0.78 | CYP2A6 (0.50) | RAB9ANPC1ALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL1222495 | 0.78 | SMPD1 (0.51) | RAB9ANPC1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL2492199 | 0.77 | TDO2 (0.42) | RAB9ANPC1NOTUMTSHRSMN1; SMN2 | |
| SCHEMBL3677936 | 0.73 | NOTUM (0.45) | RAB9ANPC1ALDH1A1NOTUMNR1H4 | |
| SCHEMBL3683732 | 0.71 | NPC1 (0.39) | RAB9ANPC1ALDH1A1NOTUMSMN1; SMN2 | |
| SCHEMBL69494 | 0.71 | RAB9A (0.45) | RAB9ANPC1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5965141 | 0.71 | NPC1 (0.42) | RAB9ANPC1ALDH1A1NOTUMSMN1; SMN2 | |
| SCHEMBL2821900 | 0.71 | ALDH1A1 (0.44) | RAB9ANPC1ALDH1A1ALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850253-B | 5-Phenylisoxazol-3-yl derivatives and application thereof in preparation of antitumor drugs | 吉林医药学院 | 2024-04-26 | — | — | CN | claimed |
| CN-115850253-A | 5-phenylisoxazol-3-yl derivative and application thereof in preparation of antitumor drugs | 吉林医药学院 | 2023-03-28 | — | — | CN | claimed |
| CN-114315670-A | SIRT2/HDAC6 dual-target inhibitor and application thereof | 贵州医科大学 | 2022-04-12 | — | — | CN | claimed |
| CN-106117156-B | compound containing 5-phenyl isoxazole stilbenoid group and preparation method thereof | 南通大学 | 2019-12-17 | — | — | CN | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| CN-106164060-A | Oxirane compound and method for producing nitrogen-containing heterocyclic compound using same | 日本电石工业株式会社 | 2016-11-23 | — | — | CN | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | claimed |
| WO-1999019304-A9 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | UPJOHN CO (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| CN-1183773-A | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | UPJOHN CO (US) | 1998-06-03 | — | — | CN | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| CN-1134697-A | Pyrimidine-sulfanyl and alkyl ether compounds | UPJOHN CO (US) | 1996-10-30 | — | — | CN | claimed |
| EP-0728130-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013267-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | THE UPJOHN COMPANY (US) | 1995-05-18 | — | — | WO | claimed |
| EP-0017738-B1 | AN INSECTICIDAL AND MITICIDAL COMPOSITION WHICH CONTAINS A CARBAMATE AND AN ORGANIC PHOSPHORUS COMPOUND, AND A METHOD OF CONTROLLING INSECTS AND MITES THEREWITH | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-08 | — | — | EP | claimed |
| US-4183856-A | FROM HETEROAROMATIC SECONDARY AMINES AND CARBAMOYL HALOGENIDES IN THE PRESENCE OF A LEWIS ACID | SHIONOGI & CO., LTD. (JP) | 1980-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | RAB9A 1172/4885NPC1 653/4885ALDH1A1 953/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | RAB9A 1172/4885NPC1 653/4885ALDH1A1 953/4885 |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | HTR5A, HTR2A, HTR1A | RAB9A 1172/4885NPC1 653/4885ALDH1A1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.